The evaluation of a gamified mobile app for depression underscores the increasing relevance of digital therapeutics in mental health. As traditional treatment modalities face competition from innovative digital solutions, pharma companies must adapt their strategies to incorporate these advancements to maintain market relevance. Regulatory context from FDA (Real-World Evidence Submissions to the Center for Drug Evaluation and Research) supports the near-term read. Assessment grounded in 22 ranked evidence items (12 high-relevance).